TY - JOUR
T1 - Differential response of glioma stem cells to arsenic trioxide therapy is regulated by MNK1 and mRNA translation
AU - Bell, Jonathan B.
AU - Eckerdt, Frank
AU - Dhruv, Harshil D.
AU - Finlay, Darren
AU - Peng, Sen
AU - Kim, Seungchan
AU - Kroczynska, Barbara
AU - Beauchamp, Elspeth M.
AU - Alley, Kristen
AU - Clymer, Jessica
AU - Goldman, Stewart
AU - Cheng, Shi Yuan
AU - James, C. David
AU - Nakano, Ichiro
AU - Horbinski, Craig
AU - Mazar, Andrew P.
AU - Vuori, Kristiina
AU - Kumthekar, Priya
AU - Raizer, Jeffrey
AU - Berens, Michael E.
AU - Platanias, Leonidas C.
N1 - Funding Information:
This work was supported by the NIH Grants CA121192, CA77816, and CA155566, U01CA168397 and by grant I01CX000916 from the Department of Veterans Affairs. J.B. Bell was supported in part by the MSTP NIH training grant T32 GM008152. E.M. Beauchamp and H.D. Dhruv were supported in part by The Ben and Catherine Ivy Foundation.
Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2018/1
Y1 - 2018/1
N2 - Mesenchymal (MES) and proneural (PN) are two distinct glioma stem cell (GSC) populations that drive therapeutic resistance in glioblastoma (GBM). We screened a panel of 650 small molecules against patient-derived GBM cells to discover compounds targeting specific GBM subtypes. Arsenic trioxide (ATO), an FDA-approved drug that crosses the blood-brain barrier, was identified as a potent PN-specific compound in the initial screen and follow-up validation studies. Furthermore,MESandPNGSCs exhibited differential sensitivity to ATO. As ATO has been shown to activate the MAPK-interacting kinase 1 (MNK1)-eukaryotic translation initiation factor 4E (eIF4E) pathway and subsequent mRNA translation in a negative regulatory feedback manner, the mechanistic role of ATO resistance in MES GBM was explored. In GBM cells, ATO-activated translation initiation cellular events via theMNK1-eIF4E signaling axis. Furthermore, resistance toATOin intracranial PDX tumors correlated with high eIF4E phosphorylation. Polysomal fractionation and microarray analysis of GBM cells were performed to identify ATO's effect onmRNAtranslation and enrichment of anti-apoptotic mRNAs in the ATO-induced translatome was found. Additionally, it was determined thatMNK inhibition sensitized MES GSCs to ATO in neurosphere and apoptosis assays. Finally, examination of the effect of ATO on patients from a phase I/II clinical trial of ATO revealed that PN GBM patients responded better to ATO than other subtypes as demonstrated by longer overall and progression-free survival. Implications: These findings raise the possibility of a unique therapeutic approach for GBM, involving MNK1 targeting to sensitize MES GSCs to drugs like arsenic trioxide.
AB - Mesenchymal (MES) and proneural (PN) are two distinct glioma stem cell (GSC) populations that drive therapeutic resistance in glioblastoma (GBM). We screened a panel of 650 small molecules against patient-derived GBM cells to discover compounds targeting specific GBM subtypes. Arsenic trioxide (ATO), an FDA-approved drug that crosses the blood-brain barrier, was identified as a potent PN-specific compound in the initial screen and follow-up validation studies. Furthermore,MESandPNGSCs exhibited differential sensitivity to ATO. As ATO has been shown to activate the MAPK-interacting kinase 1 (MNK1)-eukaryotic translation initiation factor 4E (eIF4E) pathway and subsequent mRNA translation in a negative regulatory feedback manner, the mechanistic role of ATO resistance in MES GBM was explored. In GBM cells, ATO-activated translation initiation cellular events via theMNK1-eIF4E signaling axis. Furthermore, resistance toATOin intracranial PDX tumors correlated with high eIF4E phosphorylation. Polysomal fractionation and microarray analysis of GBM cells were performed to identify ATO's effect onmRNAtranslation and enrichment of anti-apoptotic mRNAs in the ATO-induced translatome was found. Additionally, it was determined thatMNK inhibition sensitized MES GSCs to ATO in neurosphere and apoptosis assays. Finally, examination of the effect of ATO on patients from a phase I/II clinical trial of ATO revealed that PN GBM patients responded better to ATO than other subtypes as demonstrated by longer overall and progression-free survival. Implications: These findings raise the possibility of a unique therapeutic approach for GBM, involving MNK1 targeting to sensitize MES GSCs to drugs like arsenic trioxide.
UR - http://www.scopus.com/inward/record.url?scp=85040257180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040257180&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-17-0397
DO - 10.1158/1541-7786.MCR-17-0397
M3 - Article
C2 - 29042487
AN - SCOPUS:85040257180
VL - 16
SP - 32
EP - 46
JO - Cell Growth and Differentiation
JF - Cell Growth and Differentiation
SN - 1541-7786
IS - 1
ER -